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Abstract
FOXE1 is a thyroid-specific transcription factor essential for thyroid gland development 
and maintenance of the differentiated state. Interestingly, a strong association has been 
recently described between FOXE1 expression and susceptibility to thyroid cancer, but 
little is known about the mechanisms underlying FOXE1-induced thyroid tumorigenesis. 
Here, we used a panel of human thyroid cancer-derived cell lines covering the spectrum 
of thyroid cancer phenotypes to examine FOXE1 expression and to test for correlations 
between FOXE1 expression, the allele frequency of two SNPs and a length polymorphism 
in or near the FOXE1 locus associated with cancer susceptibility, and the migration 
ability of thyroid cancer cell lines. Results showed that FOXE1 expression correlated with 
differentiation status according to histological sub-type, but not with SNP genotype or cell 
migration ability. However, loss-and-gain-of-function experiments revealed that FOXE1 
modulates cell migration, suggesting a role in epithelial-to-mesenchymal transition (EMT). 
Our previous genome-wide expression analysis identified Zeb1, a major EMT inducer, as 
a putative Foxe1 target gene. Indeed, gene silencing of FOXE1 decreased ZEB1 expression, 
whereas its overexpression increased ZEB1 transcriptional activity. FOXE1 was found to 
directly interact with the ZEB1 promoter. Lastly, ZEB1 silencing decreased the ability of 
thyroid tumoral cells to migrate and invade, pointing to its importance in thyroid tumor 
mestastases. In conclusion, we have identified ZEB1 as a bona fide target of FOXE1 in 
thyroid cancer cells, which provides new insights into the role of FOXE1 in regulating cell 
migration and invasion in thyroid cancer.
Introduction
Thyroid cancer is the most commonly occurring 
endocrine malignancy and its incidence has steadily 
increased over the last four decades, accounting for 
1% of all annual cancer diagnoses (Davies & Welch 
2006, Lim et  al. 2017). Papillary thyroid carcinoma 
(PTC), a carcinoma of follicular cell origin, is the most 
frequent form of differentiated thyroid carcinoma and 
represents 80–85% of all thyroid malignancies (Zaballos 
& Santisteban 2017).
Initiation and progression of thyroid cancer results 
from the acquisition of multiple genetic alterations. PTC 
is mostly driven by mutations that activate the MAPK 
(mitogen-activated protein kinase) signaling pathway 
(Zaballos & Santisteban 2017), which includes mutations 
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in the intracellular transducer RAS and the serine/
threonine kinase BRAF, and rearrangements in the cell 
membrane receptor tyrosine kinase RET (DeLellis 2006, 
Riesco-Eizaguirre & Santisteban 2016). Beyond these 
somatic alterations, PTC displays a strong hereditary 
component, since it shows the highest familial relative 
risk (8.60–10.30) in first-degree relatives of probands 
among cancers not displaying Mendelian inheritance 
(Goldgar et al. 1994, Pal et al. 2001).
Genome-wide association studies (GWAS) have 
identified SNPs associated with PTC risk (Gudmundsson 
et al. 2009, Matsuse et al. 2011, Mancikova et al. 2015). 
These allelic variations include rs965513, found in 
the proximal region of the FOXE1 (Forkhead Box E1) 
gene (approximately 57 kb from the FOXE1 locus) 
and rs1867277, within its promoter (NM_004473.3:c. 
−283G>A), and both are strongly associated with an 
increased risk of PTC (Landa et al. 2009, Gudmundsson 
et al. 2012, Jones et al. 2012).
FOXE1, formerly known as thyroid transcription 
factor-2, is located on chromosome 9q22 in humans 
and encodes a DNA-binding protein belonging to 
the forkhead/winged-helix family, a superfamily of 
evolutionarily conserved transcriptional regulators that 
share a highly conserved forkhead box or winged helix 
DNA-binding domain (Chadwick et al. 1997, Cuesta et al. 
2007). This transcription factor possesses a polymorphic 
polyalanine (poly-A) tract just distal to its DNA-binding 
domain (rs71369530), which varies between 11 and 22 
alanine residues, although FOXE114Ala and FOXE116Ala 
account for greater than 98% of reported alleles (Macchia 
et al. 1999, Kallel et al. 2010).
FOXE1 is a thyroid-specific transcription factor 
that, together with PAX8 and NKX2-1, coordinately 
maintains the differentiated state of the thyroid gland 
and is also essential for its correct development (Zannini 
et  al. 1997, Fernandez et  al. 2015). Foxe1 is also a key 
player in thyroid organogenesis, as its expression during 
early thyroid development is required for thyrocyte 
precursor migration (De Felice et al. 1998, De Felice & Di 
Lauro 2004, Parlato et  al. 2004, Fernandez et  al. 2015). 
In the differentiated thyroid, Foxe1 is a transcriptional 
activator of the thyroperoxidase and thyroglobulin 
genes and mediates the ability of cells to respond to 
external stimuli including thyroid stimulating hormone, 
insulin-like growth factor-1, and transforming growth 
factor-β (Santisteban et al. 1992, Ortiz et al. 1999, Lopez-
Marquez et al. 2019). A previous genomic study by our 
group in a rat thyroid follicular cell line identified two 
thyroid-specific genes (Duox2 and Slc5a5) among other 
genes (including Cdh1 and Nr4a2) as novel Foxe1 targets 
(Fernandez et al. 2013).
Increasing evidence from genetic studies associates 
FOXE1 with PTC, implicating it as a susceptibility gene in 
thyroid cancer; however, its involvement in the initiation 
and progression of these tumors is unknown. Likewise, 
several studies have reported the likely contribution 
of FOXE1 to carcinogenesis in breast cancer (Park et  al. 
2012), pancreatic cancer (Sato et  al. 2003), and basal 
and squamous cell carcinomas of the skin (Eichberger 
et al. 2004, Venza et al. 2010). In the context of thyroid 
carcinoma, several studies have focused on relating FOXE1 
expression and localization in cancer cells to tumor 
development. For instance, FOXE1 overexpression has 
been described in PTC (Nonaka et al. 2008, Bychkov et al. 
2013), as well as a gradual decrease in its nuclear expression 
according to the degree of tumor dedifferentiation, along 
with cytoplasmic accumulation (Zhang et al. 2006). This 
abnormal localization of FOXE1 could be related to 
thyroid tumorigenesis. In addition, an association has 
been described between the FOXE1 poly-A repeat region 
and PTC (Bullock et al. 2012).
These observations, together with the genetic studies 
associating SNPs in and near the FOXE1 locus with 
thyroid cancer risk, and the altered expression of FOXE1 
(Landa et al. 2009, He et al. 2015a, Wang et al. 2017), have 
motivated us to further investigate the role of FOXE1 in 
thyroid cancer, to try to better understand the dual role 
of this transcription factor as both a differentiation and 
a tumoral factor. Accordingly, in the present study we 
analyzed FOXE1 expression levels in different thyroid 
cancer cell lines and looked for potential correlations 
with the genotypes of SNPs rs965513 and rs1867277 and 
with the length polymorphism rs71369530. Furthermore, 
we explored FOXE1-mediated regulation of epithelial-
to-mesenchymal transition (EMT) by analyzing the 
expression of new genes regulated by FOXE1 in thyroid 
cells. Among them, ZEB1, a major EMT inducer, emerged 
as a putative FOXE1 target gene. Lastly, we studied the 
mechanism by which FOXE1 controls ZEB1 in thyroid 
cancer cell lines and demonstrated the involvement of 
ZEB1 in the regulation of EMT in thyroid cancer cells.
Methods and materials
Cell culture
Human thyroid cancer cell lines were obtained from the 
following sources: BCPAP and NIM from Dr M Santoro 
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(University of Federico II, Naples, Italy); C643, Hth7, 
Hth83, and SW1736 from Dr N E Heldin (University 
of Uppsala, Uppsala, Sweden); FTC-133, K1 and 
Nthy-Ori-3.1 from the European Collection of 
Authenticated Cell Cultures (ECACC; Salisbury, Wiltshire, 
UK); WRO-82-1 from Dr G J F Juillard (University of 
California-Los Angeles School of Medicine, Los Angeles, 
CA, USA); TPC1 from Dr A P Dackiw (Johns Hopkins 
University, Baltimore, MD, USA); KTC-1 and KTC-2 
from Dr Junichi Kurebayashi (Kawasaki Medical School, 
Japan); Cal62, ML-1, TT206-C09, and 8505c from the 
Leibniz-Institut  DSMZ-German Collection of 
Microorganisms and Cell Cultures (Braunschweig, Germany); 
T235 and T238 from Dr Lucia Roque (Portuguese Cancer 
Institute, Lisbon, Portugal); and OCUT2 from Dr James A 
Fagin (Memorial Sloan Kettering Cancer Center, New York, 
NY, USA). All thyroid cancer cell lines and HeLa cells were 
grown in Dulbecco’s modified Eagle’s medium (DMEM). 
The human thyroid cell line Nthy-Ori-3.1 (ECACC 
#90011609) was grown in Roswell Park Memorial Institue 
1640 medium. All growth media were supplemented 
with 10% fetal bovine serum (FBS), 50 U/mL penicillin, 
50 μg/mL streptomycin, and 2 mmol/l-glutamine.
PCCl3 thyroid follicular cells, a continuous rat 
differentiated cell line, were cultured in Coon’s modified 
Ham’s F-12 medium supplemented with 5% donor calf serum 
(Thermo Fisher Scientific), and a six-hormone medium 
mixture: 1 nmol/L bovine thyroid-stimulating hormone, 
10 μg/mL insulin, 10 ng/mL somatostatin, 5 μg/mL 
transferrin, 10 nmol/L hydrocortisone, and 10 ng/mL glycyl-
l-histidyl-l-lysine acetate; all from Sigma-Aldrich.
All cell lines were used up to ten passages, maintained 
in 5% v/v CO2 at 37°C, and authenticated every 6 months 
by short tandem repeat profiling using the Applied 
Biosystems Identifier kit, at the Genomic Facility, Institute 
of Biomedical Research (IIBm; Madrid, Spain).
RT-qPCR
RNA was extracted with TRIzol (Thermo Fisher Scientific), 
and 1 µg was added to a reverse-transcriptase reaction 
mix (M-MLV; Promega Co.,). Quantitative PCR (qPCR) 
was conducted on the Mx3000P QPCR platform (Agilent 
Technologies). Reactions were performed in triplicate 
with the indicated primers and templates using the KAPA 
SYBR FAST qPCR Master Mix (Merck KGaA) for 40 cycles. 
Relative gene expression levels were quantified using 
the comparative threshold cycle 2−ΔΔCt method (Livak & 
Schmittgen 2001) by normalizing transcript levels to the 
expression of a housekeeping gene. The sequences of the 
specific primers purchased from Sigma-Aldrich are listed 
in Supplementary Table 1 (see section on supplementary 
materials given at the end of this article).
Western blotting
Total protein extracts were obtained by scraping cells 
in RIPA buffer containing a protease inhibitor cocktail 
(Roche). Equal amounts of protein (30 µg) were separated 
by SDS-PAGE, transferred to nitrocellulose membranes, 
blocked, and incubated overnight with primary antibodies 
diluted in phosphate buffered saline (PBS) 0.1% v/v Tween 
20 containing 5% w/v nonfat dry milk. Horseradish 
peroxidase (HRP)-conjugated secondary antibodies were 
incubated for 1 h at room temperature and binding was 
detected using enhanced chemiluminescence reagents 
(Thermo Fisher Scientific). The following antibodies 
were used in this study: anti-rat Foxe1 (#PA0200, Biopat 
Milan, Italy); anti-human FOXE1 (#ab5080, Abcam); anti-
E-cadherin (#BD 610182; BD Biosciences, Bedford, MA); 
anti-ZEB1 (D80D3 #3396; Cell Signaling Technology), and 
anti-β-actin (#sc-1616; Santa Cruz Biotechnology).
SNP genotyping
Genomic DNA from thyroid cell lines was extracted using 
the traditional saline method. DNA regions containing 
the two thyroid cancer-associated SNPs and the poly-A 
tract were amplified by PCR using specific primer pairs 
(Supplementary Table 2). PCR amplification was performed 
using KAPA Taq DNA polymerase (Merck KGaA) in a total 
volume of 15 μL containing 50 ng of DNA. PCR products 
were purified using the PureLink PCR Purification Kit 
(Invitrogen). Sequence analysis was performed on the ABI 
3700 automated DNA sequencer (Applied Biosystems) 
using BigDye Terminator chemistry.
RNA interference, plasmids, and transfection
For FOXE1 gene silencing studies, cells were transfected 
with 25 nmol/L of FOXE1 siRNA (RatFoxe1 ON-TARGET 
Plus SMART pool or HumanFOXE1 ON-TARGET Plus 
SMART pool) or with scrambled siRNA (ON-TARGET Plus 
Non-targeting pool) using Dharma-FECT 1 Transfection 
Reagent (Dharmacon). For ZEB1 gene silencing 
studies, human ZEB1 silencer® select siRNAs n269441 
(siZEB1-1) and n269443 (siZEB1-2) were used (Thermo 
Fisher Scientific) following the same procedure as 
described previously. For FOXE1 overexpressing studies, 
1.5 µg of human FOXE-Flag or empty-Flag expression 
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vectors (Clifton-Bligh et al. 1998, Carre et al. 2007) were 
transiently transfected. The day before transfection, cells 
were seeded in a six-well culture plate at a density of 2 × 105 
cells per well. Samples were harvested in duplicate at 
different time points (24, 48, and 72 h) after transfection, 
and total RNA and protein was extracted.
Chromatin immunoprecipitation and electrophoretic 
mobility shift assay
Chromatin immunoprecipitation (ChIP) was performed 
as previously described (Fernandez et al. 2013) using the 
HighCell ChIP Kit (Diagenode Inc., Denville, NJ, USA). 
Cross-linked PCCl3 chromatin was immunoprecipitated 
using a polyclonal antibody against Foxe1 (Biopat, Milan, 
Italy). Two independent ChIP experiments were carried 
out using two different batches of Foxe1 antibody. 
Immunoprecipitated Foxe1 and input samples were 
assayed by qPCR using specific primers for the analyzed 
region on the Zeb1 promoter (Supplementary Table 3). 
The known Foxe1 target Tpo was used as a positive control 
for immunoprecipitation, whereas two regions located 
−2 kb (cis 2 kb) and −2.5 kb (cis 2.5 kb) upstream of the 
transcription start site were used as negative controls. 
PCR reactions were performed in triplicate using the SYBR 
Green PCR Kit (Kapa Biosystems, Woburn, MA, USA). The 
enrichment of target sequences in ChIP experiments was 
calculated relative to the negative controls and normalized 
to their relative amplification in the input sample (Ruiz-
Llorente et al. 2012).
Electrophoretic mobility shift assays were 
performed using an oligonucleotide probe derived 
from the in silico-identified FOXE1-binding site 
within the human ZEB1 promoter (Oligo FOXE1: 
5′-ATTCAAATAAACACTTGCATTTTA-3′). As a control, the 
Foxe1-binding site oligonucleotide derived from the rat 
Tpo promoter was used (Aza-Blanc et al. 1993). Probes were 
labeled with [γ32P]-ATP using T4 polynucleotide kinase 
(Promega) and purified using Quick Spin G-25 Sephadex 
columns (Roche Life Sciences). Recombinant FOXE1 
was produced by in vitro transcription-translation using 
the TNT-coupled reticulocyte lysate system (Promega) 
and incubated with the labeled probe. Binding reactions 
were performed in a buffer containing 40 mmol/L 
Hepes, pH 7.9, 75 mmol/L KCl, 0.2 mmol/L EDTA, 
0.5 mmol/L dithiothreitol, 150 ng/μL poly(dI-dC), and 
5% w/v Ficoll at room temperature for 30 min. Samples 
were electrophoresed on a 5% w/v polyacrylamide gel 
in 0.5× Tris borate-EDTA. For competition, a 100-fold 
excess of the same (‘related’) or different (‘unrelated’) 
unlabeled oligonucleotides were used, as indicated in 
each experiment.
Luciferase assay
HeLa cells were seeded at a density of 2 × 105 cells 
per well in six-well tissue culture plates 24 h before 
transfection. Transfections were performed using the 
calcium phosphate co-precipitation method (Chen & 
Okayama 1988). The human ZEB1 gene promoter (Dave 
et al. 2011) was transiently transfected alone (1.5 µg) or in 
combination with 0.5 µg of a human FOXE-Flag (Clifton-
Bligh et  al. 1998, Carre et  al. 2007) expression vector. 
One hundred nanograms of the CMV Renilla vector were 
cotransfected to assess transfection efficiency. After 48 h, 
cells were harvested, lysed, and analyzed for Luciferase 
and Renilla activities using the Dual-Luciferase Reporter 
Assay System (Promega).
Migration assay
Cell migration was evaluated using scratch wound healing 
assays. Cells were seeded on a six-well plate and allowed 
to reach confluence. Twenty-four hours after transfection, 
cells were treated for 2 h with 10 µg/mL mitomycin C 
in medium with 10% FBS to inhibit proliferation. After 
treatment, a single wound in the center of cell monolayer 
was made with a 10 μL pipette tip and cell debris was 
removed by washing with PBS. After 4, 8, 24, and 48 h 
of incubation in serum-free medium, the wound closure 
areas were visualized under an inverted microscope and 
imaged. Each experiment was performed in triplicate.
Invasion assay
Cell invasion/migration was analyzed in Transwell assays 
using BD BioCoat Matrigel Invasion Chambers (BD 
Biosciences). In total, 2 × 105 cells were suspended in 500 µL 
of serum-free medium and seeded into the upper chamber. 
The lower chamber of the Transwell was filled with 500 
µL DMEM containing 20% FBS as a chemoattractant. 
After 18 h of incubation, cells on the surface of upper 
chamber were removed by scraping with a cotton swab. 
The invaded/migrated cells on the lower surface of the 
filter were fixed with 4% v/v paraformaldehyde, stained 
with 0.1% w/v crystal violet, imaged, and quantified by 
counting cells in five random fields. Experiments were 
performed three times in triplicate.
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The TCGA database was queried to assess the correlations 
between mRNA levels and clinical features. Firebrowse 
(http://firebrowse.org) was used to analyze FOXE1 mRNA 
levels in different tumor types. The cBioPortal (http://www.
cbioportal.org) and the Cancer Regulome Explorer (http://
explorer.cancerregulome.org) data portals were used to 
obtain the correlations using the thyroid carcinoma dataset 
(THCA).
Microarray data of FOXE1 levels in anaplastic thyroid 
carcinomas (ATCs) comparing with normal thyroid tissues 
were searched in The Gene Expression Omnibus (GEO) 
database. Two microarray datasets GSE33630 (Tomas et al. 
2012) and GSE65144 (von Roemeling et  al. 2015) were 
analyzed.
Statistical analysis
All data are reported as mean ± s.e.m. or mean ± s.d. 
Comparisons between two groups were made using two-
tailed Student’s unpaired t-test. Statistical analysis was 
performed with GraphPad Prism software (GraphPad 
Software Inc.). Differences were considered statistically 
significant at P < 0.05. Associations between TCGA data 
and differentiation score and between FOXE1 expression 
and migration were assessed using Pearson’s (r) test.
Results
FOXE1 expression levels correlate with 
differentiation status in human thyroid cancer 
cell lines
Given that FOXE1 has been described as a susceptibility 
gene in thyroid cancer, we first compared its level of 
expression in a panel of human thyroid cancer cell lines 
with its expression in the normal (immortalized) thyroid 
follicular cell line NThy-ori-3-1 (NThyOri). The cell lines 
used covered the spectrum of thyroid neoplasms, from 
well-differentiated PTC and follicular thyroid carcinomas 
(FTC) to anaplastic (undifferentiated) thyroid carcinoma 
(ATC), which is the most aggressive malignancy. Although 
there were some exceptions, overall FOXE1 mRNA levels 
were significantly higher in control and in PTC-derived 
cells than in FTC-derived cells, with the lowest expression 
observed in ATC-derived cell lines (Fig. 1A and B). Western 
blotting analysis of FOXE1 protein confirmed the RNA 
expression data, showing significantly higher expression 
Figure 1
FOXE1 expression in thyroid cancer cell lines. (A) FOXE1 relative mRNA expression in thyroid cell lines. Gene expression was normalized to expression of 
GAPDH. Values represent mean ± s.e.m. of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 vs NThyORI control cells. (B) FOXE1 
relative mRNA expression according to tumor subtype-cell origin. Values represent mean ± s.e.m. **P < 0.01 vs NThyORI control cells. (C) Upper panel: 
Representative Western blot of three independent experiments showing FOXE1 protein levels in thyroid cell lines. Actin was used as a loading control. 
Lower panel: FOXE1 protein expression in thyroid cell lines normalized to expression of actin. Values represent mean ± s.e.m. of three independent 
experiments. *P < 0.05, **P < 0.001, and ***P < 0.001 vs NThyORI control cells.
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in PTC cells than in FTC and ATC cells, with some ATC 
lines having almost undetectable levels of FOXE1 (Fig. 1C). 
These results indicate that FOXE1 expression positively 
correlates with the differentiation status according to the 
histological sub-type origin of cell lines.
To extend these observations to human tumors in 
general and in particular to thyroid tumors, we analyzed 
the pattern of FOXE1 expression in a range of tumor 
samples and normal tissues using data acquired from 
The Cancer Genome Atlas (TCGA) (The Cancer Genome 
Atlas 2014) using the FireBrowse and Morpheus tools. 
We observed that FOXE1 levels were elevated in several 
cancer types, with the most striking changes seen in 
esophagus and lung squamous cell carcinomas (Fig. 2A). 
By contrast, the expression levels of FOXE1 in PTC and 
normal thyroid tissue were very similar (normal tissue 
n = 59, tumor samples n = 501) (Fig. 2B). Of note, the 
levels of FOXE1 in thyroid metastases (n = 8) were similar 
to those of the primary tumor samples and normal 
tissue (Fig. 2B), suggesting a role for FOXE1 in tumor 
progression. To further explore the implications of FOXE1 
in thyroid cancer, we examined for correlations with 
aggressive clinical features. TCGA data from the public 
databases cBioportal and Cancer Regulome (Cerami et al. 
2012, Gao et al. 2013) indicated that FOXE1 levels did not 
correlate with the risk of recurrence or with extrathyroidal 
extension (Supplementary Fig. 1A). However, we observed 
a clear correlation between FOXE1 expression and the 
differentiation state in PTC tumors (Fig. 2C), which is 
consistent with the data acquired in the thyroid tumor 
cells lines. This was also confirmed after analyzing FOXE1 
expression levels in a genome array of human tumors 
that encompass all histological variants (data not shown) 
(Oncomine Data Set (www.oncomine.org)) (Giordano 
et al. 2006). In addition, microarray studies have shown 
that FOXE1 is among the 15 most downregulated genes 
in ATC (Tomas et  al. 2012, von Roemeling et  al. 2015) 
(Supplementary Fig. 1B).
Genotyping of cancer risk FOXE1 SNPs rs965513 
rs1867277 and the FOXE1 poly-alanine repeat region 
(rs71369530) in thyroid cancer cell lines
Association studies have identified two SNPs that are 
clearly linked to PTC and FTC in multiple populations 
(Wang et al. 2018). Both rs1867277 and rs965513 SNPs 
are located in the same disequilibrium block; that is, 
their alleles co-occur on the same haplotype more 
often than is expected by chance and are located 238 
bp and 57 kb upstream of the FOXE1 transcription start 
site, respectively (Gudmundsson et  al. 2009, Landa 
et al. 2009). In addition, an association has been found 
between the SNP genotypes and expression levels of 
FOXE1. Thus, it was reported that in unaffected thyroid 
tissue, FOXE1 expression was significantly lower in 
patients with the rs965513 AA genotype when compared 
with those with the GG genotype, but there was no 
significant correlation in PTC tumors (He et al. 2015a). 
Furthermore, the polymorphism in the length of the 
poly-A tract of FOXE1 (rs71369530), which has been 
Figure 2
FOXE1 expression in human tumors. (A) FOXE1 
relative mRNA expression in the indicated cancer 
types (CESC, cervical squamous cell carcinoma) 
obtained by Firebrowse analysis of TCGA 
database. (B) Box plot of FOXE1 mRNA expression 
levels in thyroid normal tissue, papillary thyroid 
carcinoma (PTC), and metastases: data were 
obtained from TCGA database. (C) Correlation 
between FOXE1 mRNA expression levels in thyroid 
tumors and differentiation score. Data were 
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associated with thyroid cancer (Kallel et  al. 2010), has 
been demonstrated to be in tight linkage disequilibrium 
with rs1867277, in addition to being associated 
(FOXE116Ala) with PTC (Bullock et al. 2012).
To ascertain whether a correlation exists between 
SNP haplotypes and FOXE1 expression in cancer, 
rs1867277, rs965513, and rs71369530 were genotyped 
by direct automated sequencing in the panel of human 
thyroid cancer cell lines. Allele variability was found in 
the analyzed cell lines, reflecting common variability 
in the general population, with minor allele frequency 
[A] of 0.5 for rs1867277 and 0.4 for rs965513 (Table 1). 
No significant correlation between the rs1867277 and 
rs965513 genotypes and the expression levels of FOXE1 
were observed in the thyroid cancer cell lines analyzed 
(Fig. 3A). Moreover, we failed to find a correlation 
between FOXE1 expression and the G (G/G) or A (G/A or 
A/A genotype) allele (Fig. 3B). Finally, we confirmed that 
the most frequent FOXE1 poly-A variant in our panel of 
thyroid cancer cells is FOXE114Ala followed by FOXE116Ala. 
Other repeat lengths were rare in the thyroid cancer 
cell lines (Table 1). In addition, we failed to observe any 
correlation between the FOXE1 poly-A variant and the 
expression levels of FOXE1 in the thyroid cancer cell lines 
analyzed (data not shown).
These data suggest that FOXE1 expression in tumoral 
thyroid cell lines is independent of the allele/genotype.
Analysis of migration in thyroid cancer cell lines
In an attempt to discern the role of FOXE1 in thyroid 
tumorigenesis, and considering that this gene is involved 
in the migration of thyroid cells from the pharyngeal 
floor to the trachea during development (De Felice et al. 
1998), we hypothesized that FOXE1 could be involved in 
thyroid tumor cell migration. To study intrinsic cellular 
motility, we first performed scratch wound-healing assays 
in thyroid cancer cell lines. Results showed that among 
the PTC cell lines, K1 and KTC1 showed the highest 
cellular migration, which was greater than that of control 
NThy-ori-3-1 cells (Fig. 4A and B). Likewise, the FTC cell 
lines WRO and FTC-133 and the ATC cell lines T238 and 
OCUT2 showed the greatest extent of wound closure after 
24 and 48 h (Fig. 4B). By contrast, the 8505c and C643 cell 
lines exhibited the lowest percentages of wound closure 
among ATC-derived cells (Fig. 4A and B).
We also performed Matrigel assays to evaluate the 
invasive capacity of the three PTC cell lines showing the 
greatest migration capacity compared with NThy-ori-3-1 
cells. We found that K1 cells had a significantly higher 
invasive capacity through Matrigel than KTC1, TPC1, and 
NThy-ori-3-1 cells (Fig. 4C). In turn, KTC1 and TPC1 cells 
had a significantly lower invasive capacity than control 
NThy-ori-3-1 cells (Fig. 4C). We then evaluated whether 
a correlation exists between SNP genotype, FOXE1 levels, 
Table 1 Genotypes of FOXE1 SNPs in thyroid cancer cell lines.
Cancer subtype Cell line Mutation
SNPs genotype
Other described mutationsrs1867277 rs965513 Poly Alanine
PTC BCPAP BRAF V600E G/G A/A 14/14 p53 D259Y/AKT1 copy gain
PTC K1 BRAF V600E A/A A/A 16/16 PI3KCA E542K
PTC KTC1 BRAF V600E G/A G/A 14/14 –
PTC NIM BRAF V600E G/G G/A 14/14 –
PTC TPC1 RET/PTC1 G/G G/G 14/14 –
FTC FTC-133 PTEN R130* A/A A/A 16/16 p53 R273H
FTC ML-1 – G/G G/G 14/14 p53 frameshift
FTC TT206-C09 NRAS G/A G/G 14/14 p53 R273C
FTC WRO BRAF V600E A/A G/A 14/16 –
ATC 8505c BRAF V600E G/G G/G 14/14 p53 R248G
ATC C643 HRAS A/A G/G 14/14 p53 R248Q and K286E
ATC Cal62 KRAS G/G G/G 14/14 p53 A161D
ATC HTH7 NRAS A/A G/G 14/16 p53 G245S
ATC HTH83 HRAS G/A G/G 12/14 –
ATC KTC2 BRAF V600E G/G G/G 14/14 –
ATC OCUT2 BRAF V600E G/G G/G 14/14 PI3KCA H1047R
ATC SW1736 BRAF V600E A/A G/G 14/16 p53 Null
ATC T235 BRAF V600E G/G G/G 14/14 –
ATC T238 BRAF V600E A/A G/G 16/16 p53 S183*/PI3KCA E542K
– NThyORI – G/G G/A 14/14 –
The genotypes of the rs1867277, rs965513 SNPs and the length of the poly-alanine tract are shown in the central columns. The cancer subtype from 
which the cell lines originated, as well as the driver mutations, is also shown.
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and cellular migration. We found that the accelerated 
wound closure did not correlate with expression levels of 
FOXE1 (Pearson r = −0.091) or with the presence of one 
copy of the [A] allele in rs1867277 and rs965513 (Fig. 4D).
FOXE1 regulates genes involved in  
epithelial-to-mesenchymal transition
In a previous genome-wide screening analysis in 
Foxe1-silenced rat PCCl3 cells, we identified several 
novel genes potentially regulated by Foxe1 (Fernandez 
et  al. 2013). Among the upregulated genes was Cdh1, 
which is widely involved in EMT (Peinado et al. 2004, 
Lamouille et  al. 2014). However, we were unable to 
demonstrate direct binding of Foxe1 to the Cdh1 
promoter (Fernandez et al. 2013). Using this previous 
analysis as a guide, and to assess the possible role 
of FOXE1 in regulating invasion and migration, we 
analyzed the mRNA levels of seven randomly chosen 
EMT-associated genes (Cav, Dsp, Esr1, Il1rn, Krt19, 
Mmp9, and Zeb1) from the list of putative Foxe1 targets 
(Fernandez et  al. 2013). We first silenced Foxe1 in 
PCCl3 cells and confirmed that the mRNA level of 
Foxe1 was decreased and the mRNA level of Cdh1 was 
increased as compared with control-silenced cells 
(Fig. 5A). Expression qPCR analysis of the seven genes 
showed that six genes were moderately upregulated 
and one (Zeb1) was significantly downregulated in 
Foxe1-silenced PCC13 cells (Fig. 5A), which is in accord 
with our previous expression array analysis (Fernandez 
et al. 2013). As expected, Western blotting showed that 
protein levels of Zeb1 were lower in Foxe1-silenced cells 
than in control-silenced cells, whereas the opposite was 
observed for E-Cdh1 (Fig. 5B). Although on the surface 
these results might seem contradictory considering 
that Foxe1 is a differentiation-related gene, they can be 
reconciled if Foxe1 has a bona fide role in migration and 
consequently in EMT. To test whether FOXE1 regulates 
ZEB1 abundance in human thyroid cancer cells, we 
silenced its expression in K1 cells, which exhibited 
the greatest migration and invasion ability of all the 
PTC lines analyzed. In accord with the findings in rat 
PCCI3 cells, FOXE1 silencing resulted in a significant 
decrease in ZEB1 mRNA (Fig. 5C) and protein (Fig. 5D) 
abundance, suggesting that ZEB1 is a target of FOXE1.
FOXE1 binds specifically to the ZEB1 promoter and 
regulates its transcriptional activity
Given the aforementioned results, we next searched 
for canonical FOXE1-binding sites within the proximal 
human ZEB1 promoter (±1010 bp), finding two potential 
FOXE1-binding domains (Fig. 6A). We performed 
ChIP analysis to determine whether Foxe1 binds to 
the Zeb1 promoter sequence in PCCl3 cells. We used 
a polyclonal antibody against Foxe1 and analyzed 
the immunoprecipitated DNA of two independent 
experiments using qPCR. Foxe1 binding to the Tpo 
promoter was used as a positive control (Fernandez et al. 
2013). ChIP analysis showed unequivocally that Foxe1 
interacts with the Zeb1 promoter when normalized to the 
control (Fig. 6B). Also, an electrophoretic mobility shift 
assay showed that recombinant FOXE1 binds specifically 
to the probe derived from the ZEB1 promoter (Fig. 6C).
Lastly, we cotransfected HeLa cells with a FOXE1 
expression vector and a luciferase reporter vector 
containing the ZEB1 promoter. Reassuringly, results 
showed a significant six-fold increase in ZEB1 promoter 
activity by FOXE1 expression (Fig. 6D). Overall, these 



































































No correlation between single nucleotide polymorphism genotypes and 
FOXE1 expression levels. (A) Representation of correlation of FOXE1 mRNA 
expression and genotypes (GG, AG, or AA) of rs1867277 and rs965513. 
Values represent mean ± s.e.m. (B) Box plot of FOXE1 mRNA expression in 
thyroid cancer cell lines vs genotypes with or without risk allele A of 
rs1867277 and rs965513. Values represent mean ± max to min.
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FOXE1 promotes thyroid cancer cell migration 
and invasion
We investigated whether FOXE1 affects the migration 
and invasion capability of thyroid cancer cells. We thus 
silenced FOXE1 expression in NThy-ori-3-1, K1, and 
TPC1 cells and repeated the scratch-wound and Transwell 
analysis. The results showed that FOXE1 silencing 
significantly impaired cell migration relative to control 
non-silenced cells (Fig. 7A). In addition, FOXE1 depletion 
significantly suppressed the invasion of K1 thyroid cancer 
cells in Transwell assays with Matrigel (Fig. 7B). Reciprocal 
experiments in NThy-ori-3-1, K1, and TPC1 cells showed 
that the over-expression of FOXE1 markedly increased, 
in a time-dependent manner, cell migration ability 
(Supplementary Fig. 2). These findings indicate that 
FOXE1 is closely associated with metastatic phenotypes 
of thyroid cancer cells.
ZEB1 knockdown suppresses cell migration and 
invasion in thyroid cancer cells
Given the potentially crucial role of ZEB1 in EMT, we 
hypothesized that FOXE1 may regulate the EMT process 
in thyroid cancer cells, at least partly, by targeting ZEB1. 
Thus, we examined the effects of ZEB1 silencing on cell 
migration and invasion. Wound healing and Transwell 
analysis showed that ZEB1 is likely important for the 
migration and invasion of thyroid cancer cells, as both 
parameters were decreased in silenced cells (Fig. 8A and B). 
Figure 4
Analysis of thyroid cancer cell migration and 
invasion. (A) Representative images of wound-
healing assay of PTC cell lines: K1, KTC1, and 
TPC1; FTC cell line: FTC-133; ATC cell lines: 8505c, 
OCUT2 and NThyORI cells. (B) Time course of 
wound closure in PTC-, FTC-, and ATC-derived 
cells. Cells were photographed at 0, 8, 24 and 48 
h, and wound closure area was quantified using 
ImageJ software. Bar graph shows wound closure 
after 48 h of migration. Values represent 
mean ± s.e.m. of the percentage of the closure of 
original wound from three independent 
experiments performed in triplicate. (C) NThyORI, 
K1, KTC1, and TPC1 cells were seeded in the 
upper chambers of Transwells, allowed to migrate 
for 18 h, and photographed. Left: representative 
images of the lower chamber (invading cells). 
Right: percentage of invasiveness by direct 
measurement with ImageJ. Values represent 
mean ± s.e.m. from three independent 
experiments performed in triplicate. *P < 0.05, 
**P < 0.01. (D) Correlation analysis between 
migration, SNP genotype, and FOXE1 expression 
levels. Left: representation of correlation between 
wound closure and levels of FOXE1 (Pearson 
r = −0.091). Center and Right: representation of 
the correlation between wound closure and 
genotype in rs1867277 and rs965513 (G/G; –/A).
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We also examined the expression of ZEB1 in a panel 
of human thyroid cancer cell lines, but we could not 
establish a clear correlation between ZEB1 and FOXE1 
expression (Fig. 8C).
Discussion
Beyond its role in organogenesis and differentiation 
(De Felice & Di Lauro 2004, Fernandez et  al. 2015), 
FOXE1 has been described as being strongly associated 
with susceptibility to several types of cancer (Brune et al. 
2008, Venza et al. 2010, Park et al. 2012) including PTC 
(Gudmundsson et  al. 2009, Landa et  al. 2009, Bullock 
et  al. 2012, He et  al. 2015a). These seemingly opposing 
roles are intriguing and have been the focus of our study. 
Indeed, several genes have been identified with dual roles 
as oncogenes and tumor suppressors (Shen et  al. 2018), 
but few examples exist of genes related to differentiation, 
and therefore necessary for normal cell development, 
and at the same time involved in cancer. This characteristic, 
however, has been attributed to the Forkhead-box 
family of transcription factors, as they are involved in 
differentiation, embryogenesis, longevity, DNA repair, 
and carcinogenesis (Katoh et  al. 2013). Accordingly, 
FOXE1 might also exert this dual action.
The role of Foxe1 in development and differentiation 
is well understood (Santisteban et al. 1992, Aza-Blanc et al. 
1993, Ortiz et al. 1997, 1999, De Felice et al. 1998, De Felice 
& Di Lauro 2004, Fernandez et al. 2015, Lopez-Marquez 
et al. 2019), yet little is known about its potential role in 
thyroid carcinogenesis, or how different allelic variants 
in or near FOXE1 are associated with thyroid cancer risk. 
In the present study, we characterized FOXE1 expression 
levels in a panel of thyroid cancer cell lines and analyzed 
the potential role of FOXE1 in the regulation of EMT.
FOXE1 expression levels are unaltered or are 
upregulated in human tumors, suggesting that it might 
be important in the initiation and progression of these 
tumors (Sato et  al. 2003, Eichberger et  al. 2004, Venza 
et al. 2010, Park et al. 2012, Sugimachi et al. 2016). Loss 
of thyroid-specific proteins and differentiation markers is 
common in thyroid carcinogenesis. Indeed, several studies 
have reported the abnormal expression of thyroid-specific 
transcription factors in some thyroid carcinomas and 
propose that their deregulation is a pivotal event for the 
initiation and progression of thyroid neoplasms (Fabbro 
et al. 1994, Ros et al. 1999, Zhang et al. 2006). In the case 
of FOXE1, it has been described that nuclear expression 
is lost according to the degree of tumor dedifferentiation, 
which seems to be related to the progression of thyroid 
tumorigenesis (Zhang et  al. 2006, Bychkov et  al. 2013). 
Conversely, it has also been described that FOXE1 is 
overexpressed in PTC, and shows an aberrant cytoplasmic 
location in PTC cells, which again has been related to 
cancer cell biology (Nonaka et  al. 2008, Bychkov et  al. 
2013). These two seemingly opposing processes makes the 
study of this factor in thyroid cancer challenging.
Our analysis of FOXE1 expression in a panel of 
thyroid cancer cell lines shows that FOXE1 levels 
inversely correlate with differentiation degree according 
to histological sub-type origin of cell lines, which is 
consistent with data on the expression patterns of FOXE1 
in PTC and normal tissues by TCGA and fits with data of 
FOXE1 expression in a genome array of human tumors 
that include all histological variants (Giordano et  al. 
2006). It should be mentioned that other recent studies 
have reported overexpression of FOXE1 in PTC samples as 
well as in K1 and TPC1 cell lines (Ding et al. 2019, Ma et al. 
2019), which contrasts with our data. We do not have an 
Figure 5
Experimental validation of microarray results by quantitative PCR. (A) 
Relative expression of seven EMT-specific genes in Foxe1-silenced PCCl3 
cells assessed by qPCR. Silenced Foxe1 microarray data are from 
Fernandez et al. (2013). As controls, we evaluated Foxe1 and Cdh1 mRNA 
expression levels. Relative gene expression in silenced Foxe1 (siFoxe1) 
samples was calculated using the corresponding siScramble samples as a 
reference. Values represent mean ± s.e.m. of four independent 
experiments. *P < 0.05, ***P < 0.001 vs siScramble. (B) Total protein 
extracts from PCC13 cells were analyzed to assess the protein levels of 
Foxe1, E-Cadherin, and Zeb1; tubulin was used as loading control. A 
representative Western blot of four independent experiments is shown. 
(C) FOXE1 and ZEB1 expression in the K1 thyroid cancer cell line after 48 h 
of siFOXE1 transfection assessed by qPCR analysis using the 
corresponding siScramble samples as a reference. Values are 
mean ± s.e.m. of three independent experiments. *P < 0.01 vs siScramble. 
(D) Total protein extracts were analyzed to assess the protein levels of 
FOXE1 and ZEB1 after 72 h of siFOXE1 transfection of K1 cells. Actin was 
used as a loading control. A representative Western blot analysis of four 
independent experiments is shown.
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FOXE1 binding to and transcriptional activation of the human ZEB1 promoter. (A) Chromosomal location of putative FOXE1-binding sites in the human 
ZEB1 promoter. We searched for FOXE1-binding sites in promoter regions (−1010/+26 bp relative to the transcription start site) of ZEB1. FASTA promoter 
sequence of ZEB1 was extracted from the Ensemble database (http://www.ensemble.org). (B) ChIP experiments for FoxE1 binding to Zeb1 promoter and 
qPCR analysis of immunoprecipitated chromatin in PCCl3 cells using a Foxe1 antibody. The enrichment of target sequence was calculated as the 
immunoprecipitation ratio (arbitrary units) relative to the negative control Cis 2.5 kb and normalized to the relative amplification in the input sample. A 
sequence from the Tpo promoter was used as a positive control. Values represent mean ± s.e.m. of four independent experiments each performed in 
triplicate. (C) EMSA assays were performed with a 32P-labeled probe containing the specific recognition sequence for FOXE1. The 32P-labeled probe (Oligo 
R*) was incubated alone (lane 1), with TNT-translated FOXE1 (lanes 2, 3, and 5) or with TNT-translated proteins from an empty vector (lane 4). 
Competition was performed with an excess of unlabeled related (Oligo R, lane 3) or unrelated oligonucleotides (Oligo UR, lane 5). (D) The human ZEB1 
promoter was cotransfected into HeLa cells with 3 µg of the empty expression vector or with 3 µg of a vector harboring the cDNA for FOXE1. ZEB1 
promoter activity is expressed as fold-induction relative to the activity observed with the empty expression vector. Luciferase activity was normalized to 
Renilla activity derived from the cotransfected pRL-SV40 to adjust for transfection efficiency. Values represent mean ± s.d. of four independent 
experiments. ***P < 0.001 vs control.
Figure 7
FOXE1 modulates migration and invasion in thyroid cancer cells. (A) Time course of wound closure in NThyORI, K1, and TPC1 cells silenced or not for 
FOXE1 expression (upper panel). Cells were photographed at 0, 4, 8, and 24 h, and wound closure area was quantified using ImageJ software. 
Quantification of migration rates in FOXE1-silenced cells vs control cells are shown in lower panel. Bar graph shows migration after 4, 8, and 24 h. (B) 
Invasiveness of K1 cells after FOXE1 silencing. Top: representative images of the lower chamber (invading cells). Bottom: percentage of invasiveness 
relative to siControl cells. Values represent mean ± s.e.m. from three independent experiments *P < 0.05, **P < 0.01. A full color version of this figure is 
available at https://doi.org/10.1530/ERC-19-0156.
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explanation for this apparent discrepancy other than the 
use of different antibodies in the studies; however, our 
results showing lower levels of FOXE1 in PTC cells than 
in control cells are in agreement with data from TCGA on 
more than 500 samples of patients with PTC.
We genotyped the rs1867277 and rs965513 SNPs in 
the same panel of thyroid cancer cell lines, as different 
variants in and near FOXE1 have been associated with 
the predisposition to PTC (Gudmundsson et  al. 2009, 
Landa et  al. 2009, Matsuse et  al. 2011). In this regard, 
He et al. reported that the risk [A] allele of DNA variant 
rs965513 was associated with low expression levels of 
FOXE1 in unaffected thyroid tissue, but no correlation 
was found between rs965513 genotype and FOXE1 levels 
in PTC tissues (He et al. 2015a). Further, in a functional 
study of rs1867277, Landa et  al. revealed that the risk 
[A] allele led to the differential recruitment of USF1 and 
USF2 transcription factors, affecting the transcriptional 
regulation of FOXE1 and conferring a role in the 
pathogenesis of PTC. In our correlation studies, however, 
we failed to observe an association between FOXE1 levels 
and the risk [A] allele of rs965513 or of rs1867277 in the 
thyroid cancer cell lines analyzed. A possible explanation 
for this is the complexity of the 9q22 region, as there is 
evidence supporting a different regulatory model that 
may govern FOXE1 promoter activity (He et  al. 2015b, 
Wang et  al. 2017), together with possible epigenetic 
modifications due to the proximity of CpG islands 
(Abu-Khudir et  al. 2014) and the potential involvement 
of other transcription factors (Landa et  al. 2009, Lopez-
Marquez et al. 2019). Similarly, although the existence of a 
relationship between the poly-A tract and PTC tumors has 
been described (Bullock et al. 2012), we did not observe 
this in the panel of cell lines analyzed herein.
FOXE1 plays a crucial role in thyroid morphogenesis 
by promoting thyroid precursor cell migration during 
gland development (De Felice et al. 1998), suggesting the 
involvement of FOXE1 in cell migration and EMT. We 
therefore analyzed cell migration in the panel of thyroid 
cancer cell lines in relation to FOXE1 expression and SNP 
genotype. Although FOXE1 levels positively correlated 
with migration rate in some cell lines, we could not 
establish a correlation between FOXE1 expression and the 
ability of thyroid cancer cell lines to migrate and invade. 
Nevertheless, silencing of FOXE1 expression resulted in 
impaired thyroid cancer cell migration and invasion, and 
Figure 8
ZEB1 silencing reduces migration and invasion in thyroid cancer cells. (A) Analysis of ZEB1 silencing in K1 cells (left panel). Total protein extracts were 
analyzed by Western blot to assess the protein levels of ZEB1 after 48 h of siZEB1-1 and siZEB1-2 transfection. Actin was used as a loading control.  
A representative Western blot analysis of three independent experiments is shown. Quantification of migration rates in ZEB1-silenced cells vs control  
cells is shown in the right panel. (B) Invasion ability of ZEB1-silenced K1 cells. Left: representative images of the lower chamber (invading cells). Right: 
percentage of invasiveness relative to siControl cells. Values represent mean ± s.e.m. from four independent experiments **P < 0.01. (C) Upper panel: 
Representative Western blot of three independent experiments showing ZEB1 protein levels in thyroid cell lines. Actin was used as a loading control. Lower 
panel: ZEB1 protein expression in thyroid cell lines normalized to expression of actin. Values represent mean ± s.e.m. of three independent experiments. 
*P < 0.05, **P < 0.001, ****P < 0.0001 vs NThyORI control cells. A full color version of this figure is available at https://doi.org/10.1530/ERC-19-0156.
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the opposite was observed after FOXE1 overexpression. 
Similarly, the presence of one copy of the [A] allele in 
rs1867277 and rs965513 did not significantly correlate 
with accelerated wound closure; however, it seems that 
there is a high migration capacity in cell lines containing 
the [A] risk allele of SNP rs1867277.
Foxe1 binds to DNA sequences present in the 
promoters of thyroglobulin (Santisteban et  al. 1992) 
and thyroperoxidase (Aza-Blanc et al. 1993), promoting 
their transcriptional activation. In a previous study, 
we identified novel Foxe1 downstream targets using 
expression arrays in Foxe1-silenced thyroid epithelial 
cells (Fernandez et al. 2013), supporting the involvement 
of FOXE1 in relevant biological processes and pathways. 
One of the hallmarks of EMT is the functional loss of 
E-cadherin (encoded by Cdh1), which was upregulated 
in Foxe1-silenced thyroid cells, suggesting that FOXE1 
modulates the expression of Cdh1. In this study, we 
show that ZEB1, a key factor that modulates E-cadherin 
expression and the induction of EMT, is regulated by 
FOXE1 in thyroid cells. In addition, we demonstrate a 
direct interaction of FOXE1 with the ZEB1 promoter 
and an increase in ZEB1 transcriptional activity in 
FOXE1-transfected cells. Interestingly, loss-of-function 
experiments revealed that cells silenced for ZEB1 show 
blunted migration and invasion relative to control non-
silenced cells, a behavior similar to that observed in 
silenced FOXE1 cells, which clearly demonstrates that 
FOXE1 regulates migration and invasion in thyroid 
cancer cells, at least in part, through ZEB1.
Taken all this together, we postulate that FOXE1 
has a crucial role in thyroid tumor cell migration and 
invasion, as shown by the results of loss/gain-of-function 
of FOXE1 on migration/invasion, and with the increasing 
evidence of the role of forkhead box proteins in the 
development and progression of cancer (Myatt & Lam 2007, 
Katoh et al. 2013).
Our results are also consistent with other studies, 
demonstrating that FOXE1 can interact with other factors 
and transactivate key genes in cancer such as SNAIL 
(Xu et al. 2015), an E-cadherin transcriptional repressor, 
or TERT (telomerase reverse transcriptase), which is 
coregulated by FOXE1 and the ETS factor ELK1 (Bullock 
et  al. 2016). Along this line, it would be interesting to 
search for FOXE1 interacting partners in thyroid cancer, 
which may reveal unique or separate signaling pathways.
In conclusion, we have identified ZEB1 as a bona fide 
target of FOXE1 in thyroid cancer cells, which provides 
new insights into the role of FOXE1 in regulating EMT in 
thyroid cancer.
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This is linked to the online version of the paper at https://doi.org/10.1530/
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